The Unintended Consequences Of The Swiss-EU Medtech MRA Failure
Executive Summary
Manufacturers will have to adjust to new medtech labeling rules to enter the Swiss market, but how far will patients relying on imports of low-risk medical devices be affected when the Swiss-EU MRA transition period ends?
You may also be interested in...
Swissdamed Devices Database Will Mirror Eudamed
Outside the EU and no longer enjoying an MRA with the bloc, Switzerland has had to develop its own medical device database, work on which will continue into next year.
DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care
Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.
Swiss-EU Standoff Set To End? Medtechs Eye MRA Action
Negotiations aimed at renewing the close trading relationship and barrier-free mutual market access between Switzerland and the EU got underway on 19 March. Swiss medtech companies welcomed the move, stressing the need for the defunct mutual recognition agreement to be updated.